2020
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop‐Busui R, Weinstock RS. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obesity And Metabolism 2020, 22: 2045-2054. PMID: 32573927, PMCID: PMC8009602, DOI: 10.1111/dom.14121.Peer-Reviewed Original ResearchMeSH KeywordsDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2ExenatideGlycated HemoglobinHumansHypoglycemic AgentsInsulinVenomsConceptsExenatide extended releaseResidual insulin productionBeta-cell functionType 1 diabetesC-peptidePlacebo groupPrimary outcomeWeek 12ER groupInsulin productionDetectable C-peptide levelsResidual beta-cell functionGLP-1 receptor agonistsRandomized placebo-controlled trialExtended releaseTotal insulin doseMean HbA1c levelPlacebo-controlled trialC-peptide levelsDetectable levelsCell functionShort-term improvementHbA1c levelsStudy drugAdverse events
2012
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2012, 56: 391-400. PMID: 23086558, PMCID: PMC3537871, DOI: 10.1007/s00125-012-2753-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntibodies, Monoclonal, HumanizedC-PeptideDiabetes Mellitus, Type 1FemaleGlycated HemoglobinHumansInsulinMaleConceptsC-peptide responseType 1 diabetesImmune therapyHigh C-peptide responseCentral randomisation centreChronic autoimmune processPlacebo-treated participantsPlacebo-controlled trialPrimary outcome analysisC-peptide levelsCharacteristics of patientsSubgroup of patientsC-peptide productionTeplizumab groupClinical respondersAutoimmune processPrimary outcomeExogenous insulinMixed mealSubgroup analysisResultsThirty-fourInsulin secretionTreatment benefitBaseline imbalancesTeplizumabEffects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with Type 2 diabetes uncontrolled by oral agents
Sakharova OV, Lleva RR, Dziura JD, Spollett GR, Howell SK, Beisswenger PJ, Inzucchi SE. Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with Type 2 diabetes uncontrolled by oral agents. Journal Of Diabetes And Its Complications 2012, 26: 333-338. PMID: 22541894, DOI: 10.1016/j.jdiacomp.2012.03.027.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedBlood GlucoseBody WeightCross-Over StudiesDiabetes Mellitus, Type 2FastingFemaleGlycated HemoglobinGlycation End Products, AdvancedHumansHypoglycemic AgentsInsulin GlargineInsulin LisproInsulin, Long-ActingMaleMiddle AgedPostprandial PeriodTreatment FailureTreatment OutcomeConceptsOral anti-hyperglycemic drugsPost-prandial glucoseInsulin strategiesFree fatty acidsType 2Post-prandial glucose metabolismProgressive β-cell dysfunctionType 2 diabetes patientsPost-prandial glucose levelsDaily insulin glargineInitial insulin regimenPrecursor of AGEsSingle-center studyClinical Research CenterLong-term diabetic complicationsAnti-hyperglycemic drugsType 2 diabetesΒ-cell dysfunctionCross-over designInitial insulinInsulin regimenOral agentsInsulin regimensInsulin therapyOAD therapy
2010
Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin Results of glucose clamp studies in youth with type 1 diabetes
Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA. Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin Results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care 2010, 33: 1009-1012. PMID: 20150302, PMCID: PMC2858163, DOI: 10.2337/dc09-2118.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlucose clamp studiesGlucose excursionsClamp studiesMeal-related glucose excursionsRapid-acting insulin analoguesRapid-acting insulinEuglycemic glucose clampTime-action curvePharmacodynamic peakA1c levelsTreatment burdenPharmacodynamic effectsDaily injectionsUnits/Pharmacodynamic actionClinical studiesGlucose clampMixed injectionGlargineEarly pharmacokineticsInsulin analoguesObjective clinicianInsulin pharmacokineticsLispro
2008
Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth With Type 1 Diabetes Receiving Insulin Pump Therapy
Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, Martin ML, Tamborlane WV, Weinzimer SA. Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth With Type 1 Diabetes Receiving Insulin Pump Therapy. Diabetes Care 2008, 32: 240-244. PMID: 19017777, PMCID: PMC2628686, DOI: 10.2337/dc08-0595.Peer-Reviewed Original ResearchConceptsInsulin pump therapyGlucose infusion rateType 1 diabetesDay 1Day 4Pump therapyInsulin aspartPharmacodynamic parametersInsulin actionInsulin bolusRapid acting analogsEuglycemic clamp procedureExogenous glucose infusionGIR curveEffect of agePharmacodynamic measuresPharmacodynamic characteristicsClamp procedureInfusion siteGlucose infusionInfusion rateInsulin analoguesType 1AspartOverall insulin action
2006
Optimal control of type 1 diabetes mellitus in youth receiving intensive treatment
Springer D, Dziura J, Tamborlane WV, Steffen AT, Ahern JH, Vincent M, Weinzimer SA. Optimal control of type 1 diabetes mellitus in youth receiving intensive treatment. The Journal Of Pediatrics 2006, 149: 227-232. PMID: 16887440, DOI: 10.1016/j.jpeds.2006.03.052.Peer-Reviewed Original ResearchConceptsType 1 diabetes mellitusRace/ethnicityLow socioeconomic statusSocioeconomic statusDiabetes mellitusLarge clinical practiceDuration of diabetesOptimal glycemic controlBody mass indexPoor metabolic controlAge 18 yearsGlycemic targetsInjection therapyGlycemic controlDiabetes controlMass indexFemale sexDatabase reviewInsulin administrationIntensive treatmentMonths durationTrial recommendationsMultiple linear regression analysisTherapeutic goalsClinical practice
2005
The “Obese Insulin-Sensitive” Adolescent: Importance of Adiponectin and Lipid Partitioning
Weiss R, Taksali SE, Dufour S, Yeckel CW, Papademetris X, Cline G, Tamborlane WV, Dziura J, Shulman GI, Caprio S. The “Obese Insulin-Sensitive” Adolescent: Importance of Adiponectin and Lipid Partitioning. The Journal Of Clinical Endocrinology & Metabolism 2005, 90: 3731-3737. PMID: 15797955, DOI: 10.1210/jc.2004-2305.Peer-Reviewed Original ResearchConceptsInsulin sensitivityVisceral fatLipid depositionObese insulin-resistant adolescentsObese insulin-sensitive subjectsNormal glucose tolerancePeripheral insulin sensitivityIntramyocellular lipid contentBody mass indexInsulin-sensitive subjectsHyperinsulinemic-euglycemic clampInsulin-resistant adolescentsInsulin-sensitive controlsWide interindividual variationLipid partitioningLower lipid depositionPercent body fatMagnetic resonance imagingImportance of adiponectinObese insulinObese groupGlucose toleranceMass indexObese adolescentsIntramyocellular lipids
2004
Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes: A Follow-up Report
Weinzimer SA, Ahern JH, Doyle EA, Vincent MR, Dziura J, Steffen AT, Tamborlane WV. Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes: A Follow-up Report. Pediatrics 2004, 114: 1601-1605. PMID: 15574621, DOI: 10.1542/peds.2004-0092.Peer-Reviewed Original ResearchConceptsContinuous subcutaneous insulin infusionType 1 diabetesMultiple daily injectionsSubcutaneous insulin infusionSevere hypoglycemiaDaily injectionsInsulin infusionRate of SHMonths of CSIIYoung childrenEpisodes of DKAOlder pediatric patientsVery Young ChildrenPersistence of benefitHypoglycemia frequencyYounger patientsGlycemic controlPediatric patientsPump treatmentClinic databaseSafety dataEmergency treatmentAge groupsType 1Diabetes